NERV Minerva Neurosciences, Inc.

NASDAQ
$2.63

Minerva Neurosciences, Inc. (NERV) is expected to report earnings on February 5, 2027, before the market open. The consensus earnings estimate is a loss of $0.09 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +13.4% since its last earnings release on November 6, 2026.

Minerva Neurosciences Missed Consensus Estimates
Friday, November 6, 2026 · 9:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 5
Friday · 7:00 AM ET
Earnings Whisper
-
vs ($0.09)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.54

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Minerva Neurosciences, Inc.

Minerva Neurosciences Inc is a development stage bio-pharmaceutical company. It develops experimental drugs for the treatment of schizophrenia, insomnia and Parkinson' disease.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.